Search our Database of Scientific Publications and Authors

I’m looking for a

    2522 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 51

    Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response.
    JAAD Case Rep 2018 May 31;4(4):305-309. Epub 2018 Mar 31.
    Department of Dermatology, St. Joseph Mercy Hospital, Ann Arbor, Michigan.
    We report a case of histologically confirmed primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) that subsequently underwent spontaneous regression in the absence of systemic treatment. The case showed an atypical lymphoid infiltrate that was CD20 and MUM-1 and CD10. A subsequent biopsy of the spontaneously regressed lesion showed fibrosis associated with a lymphocytic infiltrate comprising reactive T cells. Read More

    The First Year of the AEVD Primary Cutaneous Lymphoma Registry.
    Actas Dermosifiliogr 2018 Apr 18. Epub 2018 Apr 18.
    Servicio de Dermatología, Hospital Universitario 12 de Octubre, Institute i+12, Medical School. Universidad Complutense, ONCOCIBER, Madrid, España.
    Background And Objective: Primary cutaneous lymphomas are uncommon. This article describes the Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV) and reports on the results from the first year.

    Patients And Methods: Disease registry for patients with primary cutaneous lymphoma. Read More

    Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
    Blood Adv 2018 Apr;2(8):871-876
    Memorial Sloan Kettering Cancer Center, New York, NY.
    Ibrutinib has previously been shown to inhibit Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell malignancies. Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. Read More

    Small cell lymphocytic variant of marginal zone lymphoma: A distinct form of marginal zone lymphoma derived from naïve B cells as a cutaneous counterpart to the naïve marginal zone lymphoma of splenic origin.
    Ann Diagn Pathol 2018 Feb 21;34:116-121. Epub 2018 Feb 21.
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA.
    Primary cutaneous marginal zone lymphoma most commonly represents an indolent form of cutaneous B cell lymphoma. However, epidermotropic marginal zone lymphoma, blastic marginal zone lymphoma and B cell dominant variants without isotype switching can be associated with extracutaneous dissemination. The presumptive cell of origin is a post germinal center B cell with plasmacytic features. Read More

    Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
    J Natl Cancer Inst 2018 Apr 6. Epub 2018 Apr 6.
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.
    Background: It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact.

    Methods: We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014. Read More

    [MALT lymphoma with t (X;14) (p11.2;q32) developing during the course of cutaneous leukocytoclastic angitis].
    Rinsho Ketsueki 2018 ;59(3):269-274
    Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine.
    A 73-year-old man with left parotid gland swelling over 2 months was referred to our hospital in March 201X. Purpura on the lower legs had been recurrent for >20 years. Biopsy of the parotid gland demonstrated diffuse infiltration of abnormal lymphocytes that were negative for CD10 and positive for CD19, CD20, and κ-chain. Read More

    A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma leg-type.
    J Invest Dermatol 2018 Mar 26. Epub 2018 Mar 26.
    INSERM U1053, Bordeaux Research in Translational Oncology, Team 3 oncogenesis of cutaneous lymphomas, Univ. Bordeaux, Bordeaux, France; Tumor Bank and Tumor Biology Laboratory, CHU Bordeaux, Pessac,, France.
    While the combination of rituximab and polychemotherapy has improved prognosis of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), advanced age of patients limits therapeutic options in relapsing/refractory cases. A multicenter single-arm phase II trial was conducted to assess benefit and safety of lenalidomide in refractory/relapsing PCDLBCL, LT. Primary endpoint was the 6-month overall response rate (ORR). Read More

    Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.
    Mod Pathol 2018 Mar 26. Epub 2018 Mar 26.
    INSERM U1053, University of Bordeaux, 33000, Bordeaux, France.
    In nodal diffuse large B-cell lymphoma, the search for double-hit with MYC and BCL2 and/or BCL6 rearrangements or for dual expression of BCL2 and MYC defines subgroups of patients with altered prognosis that has not been evaluated in primary cutaneous large B-cell lymphoma. Our objectives were to assess the double-hit and dual expressor status in a cohort of 44 patients with primary cutaneous large B-cell lymphoma according to the histological subtype and to evaluate their prognosis relevance. The 44 cases defined by the presence of more than 80% of large B-cells in the dermis corresponded to 21 primary cutaneous follicle centre lymphoma with large cell morphology and 23 primary cutaneous diffuse large B-cell lymphoma, leg type. Read More

    Expression profiling analysis of autophagy-related genes in perineural invasion of cutaneous squamous cell carcinoma.
    Oncol Lett 2018 Apr 6;15(4):4837-4848. Epub 2018 Feb 6.
    Department of Dermatology, Chinese PLA General Hospital, Beijing 100853, P.R. China.
    The aim of the present study was to identify the potential autophagy-related genes and to explore the underlying molecular mechanisms involved in cutaneous squamous cell carcinoma of head and neck (cSCCHN) by bioinformatics analysis. The Gene Expression Omnibus (GEO) series GSE86544 was downloaded from the GEO database. The primary data was generated from cSCCHN with clinical perineural invasion (PNI) and cSCCHN without PNI, and was further analyzed in order to identify differentially expressed genes (DEGs). Read More

    Primary cutaneous follicle center lymphoma mimicking folliculitis.
    Cutis 2018 Jan;101(1):E30-E33
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, and Department of Dermatology, University of Texas Medical School, Houston, USA.
    Primary cutaneous follicle center lymphoma (PCFCL) is the most common type of cutaneous B-cell lymphoma. The cutaneous manifestations of PCFCL typically include solitary erythematous or violaceous plaques, nodules, or tumors of varying sizes. Grouped lesions also may be observed, but multifocal disease is rare. Read More

    Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia 2018 Feb 22. Epub 2018 Feb 22.
    Stem Cells and Cancer Research Laboratory, CIBERONC, Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003, Barcelona, Spain.
    Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and β-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Read More

    Primary cutaneous non-Hodgkin's lymphoma, clinically mimicking a soft tissue sarcoma.
    Cytojournal 2018 25;15. Epub 2018 Jan 25.
    Department of Surgery, PGIMER, Dr. Ram Manohar Lohia Hospital, New Delhi, India.
    Primary cutaneous B-cell lymphomas (PCBCL) are a heterogeneous group of neoplasms with distinct biology and clinical course when compared to their nodal counterparts. They usually present as violaceous, erythematous plaques, and nonulcerated nodules, which are confined to skin at the time of presentation. We present an unusual case of primary cutaneous diffuse large B-cell lymphoma, clinically mimicking a sarcoma. Read More

    Violet - Colored Inguinal Located Cutaneous Tumour?
    Open Access Maced J Med Sci 2018 Jan 13;6(1):137-138. Epub 2018 Jan 13.
    "Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria.
    Anaplastic large cell lymphoma (ALCL) represents an aggressive CD30 - positive T cell lymphoma, as it is the second most common T cell lymphoma and 2% to 5% of all non - Hodgkin lymphomas. The cutaneous involvement can be primary or secondary within systemic ALCL, resembling inflammatory and other neoplastic lesions both clinically and cytologically. Various pigmented cutaneous tumours with a different origin, cutaneous metastasis and B-cell lymphoma must be carefully considered in the differential diagnostic plan. Read More

    Delayed presentation of toxic epidermal necrolysis-like cutaneous acute graft-versus-host disease in the setting of recent immunosuppressant discontinuation.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Department of Dermatology, Northwestern University, Chicago, Illinois.
    Acute graft-versus-host disease (GvHD) is a process that classically has been defined as occurring less than 100 days after stem cell transplant. When Stage IV cutaneous acute GvHD occurs outside this window, it can be difficult to distinguish clinically from toxic epidermal necrolysis (TEN). A 50-year-old man with diffuse large B-cell lymphoma who had undergone an allogeneic stem cell transplant 20 months previously was admitted for neutropenic septic shock. Read More

    A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Oncologist 2018 Apr 7;23(4):397-e30. Epub 2018 Feb 7.
    Yale University School of Medicine, New Haven, Connecticut, USA.
    Lessons Learned: Clofarabine can be active in relapsed and refractory lymphoid malignancies on a weekly dosing schedule.Responses were seen in patients with T-cell lymphomas, including cutaneous T-cell lymphoma, but not in patients with aggressive B-cell lymphomas.

    Background: Clofarabine is a second-generation purine nucleoside analog currently approved for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia. Read More

    Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey.
    Turk J Gastroenterol 2018 01;29(1):87-91
    Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ege University School of Medicine, İzmir, Turkey.
    Background/aims: A liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in longterm survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. Read More

    Primary skeletal muscle lymphoma: A case report.
    Mol Clin Oncol 2018 Jan 3;8(1):80-82. Epub 2017 Nov 3.
    Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum 25040, Turkey.
    Primary lymphomas of the bone or skeletal muscle are rare. Three mechanisms of lymphomatous involvement of the muscle have been described, namely direct invasion from adjacent involved lymph nodes or bone, metastatic spread and, least commonly, primary muscle lymphoma. We herein present a rare case of primary mucle non-Hodgkin lymphoma with a description if the associated clinicopathological findings and a review of the relevant literature. Read More

    Epidermotropic presentation by splenic B-cell lymphoma: The importance of clinical-pathologic correlation.
    J Cutan Pathol 2018 Apr 22;45(4):299-304. Epub 2018 Feb 22.
    Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, New Hampshire, Lebanon.
    There are exceedingly rare reports of patients with epidermotropic B-cell lymphomas. A subset presented with intermittent, variably pruritic papular eruptions and involvement of their spleens, peripheral blood and bone marrow at the time of diagnosis. Furthermore, some experienced an indolent course despite dissemination of their lymphomas. Read More

    Cutaneous diffuse large B-cell lymphoma.
    Clin Case Rep 2018 Jan 28;6(1):228-229. Epub 2017 Nov 28.
    Haematology DepartmentCentro Hospitalar Vila Nova de Gaia/EspinhoRua Conceição Fernandes4434-502Vila Nova de GaiaPortugal.
    Cutaneous diffuse large B-cell lymphoma accounts for ~6% of all cutaneous lymphomas. It is associated with poor prognosis, and solitary lesions are relatively rare. It often requires an aggressive approach with multi-agent chemotherapy and radiotherapy. Read More

    Drug induced pseudolymphoma.
    Semin Diagn Pathol 2018 Jan 17. Epub 2018 Jan 17.
    Regional Medical Laboratory, 4142 South Mingo Road, Tulsa, OK 74146-3632, United States.
    Atypical lymphocytic infiltrates of the skin comprise a broad spectrum of entities ranging from benign infiltrates to those that are malignant. Many of these infiltrates are in fact reactive lymphomatoid ones related to drug therapy falling under the general category of drug associated pseudolymphoma. Within this nosologic umbrella are nodular and diffuse infiltrates resembling low grade T and B cell lymphoma consistent with lymphocytoma cutis, drug associated reversible T cell dyscrasias which draw a strong morphologic and phenotypic parallel with mycosis fungoides and the various pre-lymphomatous T cell dyscrasias, and angiocentric CD30 positive infiltrates mirroring lymphomatoid papulosis. Read More

    Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases.
    Intern Med 2018 Jan 11. Epub 2018 Jan 11.
    Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan.
    Patients with mycosis fungoides (MF), the most common subtype of primary cutaneous T-cell lymphoma, have an increased risk of developing secondary malignancies. We herein report two rare cases of MF concurring with diffuse large B cell lymphoma (B lymphoid lineage) and acute myeloid leukemia (myeloid lineage) in two otherwise healthy elderly patients. Potential etiologic factors, including the impact of the therapy-associated inflammatory response on the development of secondary tumors in patients with MF, are discussed. Read More

    Dermoscopic characterization of cutaneous lymphomas: a pilot survey.
    Int J Dermatol 2018 Mar 10;57(3):339-343. Epub 2018 Jan 10.
    Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, IA, USA.
    Background: While substantial dermoscopic analysis of melanocytic lesions has been performed, dermoscopic characterization of cutaneous lymphoid proliferations has been limited. Cutaneous lymphoma, particularly early mycosis fungoides (MF) and its variants, is often challenging to clinically and pathologically distinguish from inflammatory processes of the skin. This study aimed to survey the dermoscopic findings of cutaneous lymphomas and to discern whether any patterns might potentially serve as specific signatures. Read More

    Image Gallery: Metachronic occurrence of primary cutaneous marginal zone B-cell lymphoma and primary cutaneous Rosai-Dorfman disease in the same patient.
    Br J Dermatol 2017 Dec;177(6):e355
    Department of Pathology, University Hospital of Gran Canaria 'Doctor Negrín', Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain.

    Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.
    J Am Acad Dermatol 2018 Jan 4. Epub 2018 Jan 4.
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address:
    Background: Cutaneous lymphoma diagnosed after anti-tumor necrosis factor-α therapy (anti-TNF-α) has been reported in the literature, yet a clear link between both events remains elusive.

    Objective: To review our experience with cutaneous lymphoma diagnosed during or after the use of anti-TNF-α therapies.

    Methods: This is a multicenter retrospective study and a literature review. Read More

    Primary Cutaneous B-cell Lymphomas: Case Report of Two Cases.
    Indian J Dermatol 2017 Nov-Dec;62(6):675
    Department of Pathology, Armed Forces Medical College, Pune, Maharashtra, India.
    Primary cutaneous lymphomas are a unique, heterogeneous group of lymphoproliferative disorders which have a primary cutaneous manifestation in the absence of systemic involvement of lymph nodes, bone marrow, or visceral organs at the time of diagnosis. Among the primary cutaneous lymphomas, B-cell lymphoma is much less common and accounts for 20%-25% of cases. Primary cutaneous diffuse large B-cell lymphomas (PCDLBCLs) are aggressive neoplasms with poor prognosis. Read More

    Necrotizing fasciitis associated with primary cutaneous B-cell lymphoma. A case report.
    G Chir 2017 May-Jun;38(3):130-134
    Necrotizing fasciitis is a rapidly progressive and life-threatening infection of the deeper skin layers and subcutaneous tissues that moves along the facial planes.

    Objectives: We present the rare case of a patient with necrotizing fasciitis associated with high malignancy b-cell lymphoma. Our purpose is to investigate the probable connection between the two pathologies and evaluate the importance of early surgical intervention. Read More

    A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler Relat Disord 2018 Jan 16;19:115-117. Epub 2017 Nov 16.
    Division of Hematology, Mayo Clinic, USA. Electronic address:
    The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it. Read More

    Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study.
    Eur J Dermatol 2018 Feb;28(1):44-49
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
    Background: Primary cutaneous lymphomas (PCLs) are a rare group of extranodal non-Hodgkin lymphomas, and epidemiological data in Mediterranean countries are scarce.

    Objective: To investigate the incidence and characteristics of PCL in a single tertiary referral centre in Italy.

    Materials & Methods: A total of 141 PCL patients, seen over a 10-year follow-up period, were investigated. Read More

    Primary cutaneous follicle center lymphoma.
    An Bras Dermatol 2017 Sep-Oct;92(5):701-703
    Department of dermatology at Universidade do Estado do Pará (UEPA) - Belém (PA), Brazil.
    Cutaneous lymphomas are classified according to their cellular origin into T-cell lymphoma and B-cell lymphoma. The annual incidence rate is 0.3 per 100,000 population. Read More

    Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Cell Cycle 2018 19;17(4):468-478. Epub 2018 Feb 19.
    a Oncoceutics, Inc. , Philadelphia , PA.
    ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1-8 µM) dose- and time-dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples. Read More

    Mutations in Coagulation Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma.
    TH Open 2017 Jul;1(2):e113-e121
    Divisions of Laboratory Medicine, The University of Alabama at Birmingham, AL 35249.
    Coagulation factor VIII (FVIII), von Willebrand factor (VWF), and ADAMTS13 play an important role in regulation of normal hemostasis. However, little is known about their roles in patients with malignancy, particularly with cutaneous melanoma. Whole genome sequencing data are available for 25,719 cases in 126 cancer genomic studies for analysis. Read More

    Primary cutaneous B-cell lymphoma: narrative review of the literature.
    G Ital Dermatol Venereol 2017 Nov 16. Epub 2017 Nov 16.
    Dermatology Unit, IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
    Primary Cutaneous B-cell Lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the skin. Despite being recognized as autonomous and distinct clinico-pathologic entities since the late 80s, their classification is still an ongoing matter of debate. At the moment, WHO classification recognizes three disorders: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type. Read More

    PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Am J Surg Pathol 2018 Mar;42(3):326-334
    INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphomas.
    As checkpoint molecules' inhibition may represent a therapeutic option in relapsing cases, we assessed programmed death ligands' (PD-L1/PD-L2) expression in a series of 29 primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) cases. Double immunostaining for either PD-L1 or PD-L2 was associated either with PAX5 staining to evaluate tumor cells or with CD68 or CD163 staining for macrophages. The microenvironment of PCDLBCL-LT was characterized by immunostainings for CD3 (tumor-infiltrating lymphocytes), FOXP3 (regulatory T cells), programmed cell death-1, and CD33 (myeloid-derived suppressor cells). Read More

    Hodgkin's lymphoma arising in a case of mycosis fungoides: An unusual association.
    Indian J Dermatol Venereol Leprol 2018 May-Jun;84(3):292-297
    Department of Pathology, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India.
    Mycosis fungoides is a cutaneous T-cell lymphoma with a high risk for developing secondary malignancies, especially B-cell lymphoproliferative disorders. About 40 cases of Hodgkin's lymphoma associated with mycosis fungoides have been reported in literature till date. We report a case of a 35-year-old gentleman who presented with intensely itchy reddish lesions all over the body. Read More

    Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders.
    J Cutan Pathol 2018 Jan 22;45(1):39-47. Epub 2017 Nov 22.
    Department of Dermatology, University of Iowa, Iowa City, Iowa.
    Background: Appropriate use criteria have been developed for many tests using expert judgment, evidence-based practice and clinical experience. In this context, we report the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected.

    Methods: An Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). Read More

    Pachyderma in Primary Cutaneous NK and T-Cell Lymphoma and Leukemia Cutis.
    Case Rep Dermatol 2017 Sep-Dec;9(3):151-157. Epub 2017 Sep 11.
    Department of Dermatology, Liège University Hospital, Liège, Belgium.
    Background: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC).

    Aim: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma.

    Results: In a series of pCNKTCL ( = 70), pCBCL ( = 12), and LC ( = 2) patients followed up during 9 years, 6 cases of pachyderma were observed. Read More

    Bilateral upper and lower eyelid margin swelling and madarosis due to lymphoma.
    Surv Ophthalmol 2017 Oct 3. Epub 2017 Oct 3.
    Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Department of Ophthalmology, The Ophthalmic Plastic and Reconstructive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
    Over a 2-year period, swellings of all 4 eyelid margins developed in a 32-year-old woman and was accompanied by complete loss of eyelashes. An inflammatory dermatologic condition was considered the most likely cause. A full-thickness right lower eyelid biopsy revealed a multinodular lymphoid tumor at the eyelid margin which immunophenotypically and genetically was diagnosed as an extranodal marginal zone lymphoma. Read More

    Frequent immunoglobulin G4 expression in a common variant of primary cutaneous marginal zone B-cell lymphoma.
    Australas J Dermatol 2017 Oct 4. Epub 2017 Oct 4.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
    Immunoglobulin (Ig)G4 expression was recently observed in a proportion of primary cutaneous marginal zone B-cell lymphoma (PCMZL) with plasmacytic differentiation. IgG4-related disease is characterised by polyclonal lymphoplasmacytic infiltration with IgG4 expression, storiform fibrosis and obliterative phlebitis in histopathology. Here we report three cases of common variants of PCMZL with predominant and varied IgG4 expression, suggesting there is an underlying clonal progression between these two entities. Read More

    Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
    South Asian J Cancer 2017 Jul-Sep;6(3):129-131
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
    Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features.

    Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Read More

    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood 2017 11 2;130(19):2073-2083. Epub 2017 Oct 2.
    Department of Dermatology and.
    The presence and degree of peripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available systemic therapies for CTCL may variably decrease tumor burden and improve quality of life, but offer limited effects on survival; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted. Mutational analyses of CTCL patient peripheral blood malignant cell samples suggested the antiapoptotic mediator B-cell lymphoma 2 (BCL2) as a potential therapeutic target. Read More

    1 OF 51